LOS ANGELES, March 7 (Reuters) - Keryx Biopharmaceuticals Inc (KERX.O) said on Friday that a Phase 3 clinical trial for Sulonex, a drug designed to treat diabetic neuropathy, has failed to meet the study's primary objectives.
The company said it plans to re-focus its primary efforts and resources on rapidly moving renal disease drug Zerenex and cancer drug Perifosine forward. (Reporting by Gina Keating; editing by Carol Bishopric)
The healthcare bill will mean business as usual for investors, but what will happen in the long-term is unclear. Full Article | Video
Homebuyers are increasingly counting on their extended families to cut costs and get a bigger bang for their mortgage dollars. Full Article
Huge strides have been made in women's rights over the past 40 years. So why is Gloria Steinem still unsettled? Full Article | Video
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
